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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13349/full. Voltage-gated ion channels are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated
ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best
available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification
and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable,
point-in-time record that will survive database updates.
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CatSper and Two-Pore channels
Voltage-gated ion channels! CatSper and Two-Pore channels
Overview: CatSper channels (CatSper1-4, nomenclature as
agreed by NC-IUPHAR [64]) are putative 6TM, voltage-gated,
calcium permeant channels that are presumed to assemble as a
tetramer of α-like subunits and mediate the current ICatSper [171].
Inmammals, CatSper subunits are structurally most closely related
to individual domains of voltage-activated calcium channels (Cav)
[308]. CatSper1 [308], CatSper2 [302] and CatSpers 3 and 4 [155,
221, 299], in commonwith a putative 2TM auxiliary CatSperβ pro-
tein [218] and two putative 1TM associated CatSperγ and CatSperÆ
proteins [59, 382], are restricted to the testis and localised to the
principle piece of sperm tail.
Two-pore channels (TPCs) are structurally related to CatSpers,
CaVs and NaVs. TPCs have a 2x6TM structure with twice the num-
ber of TMs of CatSpers and half that of CaVs. There are three an-
imal TPCs (TPC1-TPC3). Humans have TPC1 and TPC2, but not
TPC3. TPC1 and TPC2 are localized in endosomes and lysosomes
[39]. TPC3 is also found on the plasma membrane and forms
a voltage-activated, non-inactivating NaC channel [40]. All the
three TPCs are NaC-selective under whole-cell or whole-organelle
patch clamp recording [41, 42, 404]. The channels may also con-
duct Ca2C [243].
Nomenclature CatSper1
HGNC, UniProt CATSPER1, Q8NEC5
Activators CatSper1 is constitutively active, weakly facilitated by membrane depolarisation, strongly augmented by intracellular alkalinisation. In human, but not mouse, spermatozoa
progesterone (EC50 8 nM) also potentiates the CatSper current (ICatSper). [215, 343]
Functional Characteristics Calcium selective ion channel (Ba2C>Ca2CMg2CNaC); quasilinear monovalent cation current in the absence of extracellular divalent cations; alkalinization shifts the
voltage-dependence of activation towards negative potentials [V1=2 @ pH 6.0 = +87 mV (mouse); V1=2 @ pH 7.5 = +11mV (mouse) or pH 7.4 = +85 mV (human)]; required
for ICatSper and male fertility (mouse and human)
Channel blockers ruthenium red (Inhibition) (pIC50 5) [171] – Mouse, HC-056456 (pIC50 4.7) [46], Cd
2C (Inhibition) (pIC50 3.7) [171] – Mouse, Ni
2C (Inhibition) (pIC50 3.5) [171] – Mouse
Selective channel blockers NNC55-0396 (Inhibition) (pIC50 5.7) [-80mV – 80mV] [215, 343], mibefradil (Inhibition) (pIC50 4.4–4.5) [343]
Nomenclature CatSper2 CatSper3 CatSper4
HGNC, UniProt CATSPER2, Q96P56 CATSPER3, Q86XQ3 CATSPER4, Q7RTX7
Functional Characteristics Required for ICatSper and male fertility
(mouse and human)
Required for ICatSper and male fertility (mouse) Required for ICatSper and male fertility (mouse)
Searchable database: http://www.guidetopharmacology.org/index.jsp CatSper and Two-Pore channels 5905
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Nomenclature TPC1 TPC2
HGNC, UniProt TPCN1, Q9ULQ1 TPCN2, Q8NHX9
Functional Characteristics Organelle voltage-gated NaC-selective channel (NaCKCCa2C); Required for the
generation of action potential-like long depolarization in lysosomes.
Voltage-dependence of activation is sensitive to luminal pH (determined from
lysosomal recordings).  1=2 @ pH4.6 = +91 mV;  1=2 @ pH6.5 = +2.6 mV. Maximum
activity requires PI(3,5)P2 and reduced [ATP]
Organelle voltage-independent NaC-selective channel (NaCKCCa2C). Sensitive to
the levels of PI(3,5)P2. Activated by decreases in [ATP] or depletion of extracellular
amino acids
Activators phosphatidyl (3,5) inositol bisphosphate (pEC50 6.5) [41] phosphatidyl (3,5) inositol bisphosphate (pEC50 6.4) [387]
Channel blockers verapamil (Inhibition) (pIC50 4.6) [41], Cd
2C (Inhibition) (pIC50 3.7) [41] verapamil (Inhibition) (pIC50 5) [387]
Comments: CatSper channel subunits expressed singly, or in
combination, fail to functionally express in heterologous expres-
sion systems [302, 308]. The properties of CatSper1 tabulated
above are derived from whole cell voltage-clamp recordings com-
paring currents endogenous to spermatozoa isolated from the cor-
pus epididymis of wild-type andCatsper1. = / mice [171] and also
mature human sperm [215, 343]. ICatSper is also undetectable
in the spermatozoa of Catsper2. = /,Catsper3. = /, Catsper4. = /,
or CatSperÆ . = / mice, and CatSper 1 associates with CatSper
2, 3, 4, β, γ, and Æ [59, 218, 299]. Moreover, targeted disrup-
tion of Catsper1, 2, 3, 4, or Æ genes results in an identical pheno-
type in which spermatozoa fail to exhibit the hyperactive move-
ment (whip-like flagellar beats) necessary for penetration of the
egg cumulus and zona pellucida and subsequent fertilization. Such
disruptions are associated with a deficit in alkalinization and
depolarization-evoked Ca2C entry into spermatozoa [47, 59, 299].
Thus, it is likely that the CatSper pore is formed by a heterote-
tramer of CatSpers1-4 [299] in association with the auxiliary sub-
units (β, γ, Æ) that are also essential for function [59]. CatSper
channels are required for the increase in intracellular Ca2C con-
centration in sperm evoked by egg zona pellucida glycoproteins
[404]. Mouse and human sperm swim against the fluid flow
and Ca2C signaling through CatSper is required for the rheotaxis
[239]. In vivo, CatSper1-null spermatozoa cannot ascend the fe-
male reproductive tracts efficiently [60, 135]. It has been shown
that CatSper channels form four linear Ca2C signaling domains
along the flagella, which orchestrate capacitation-associated tyro-
sine phosphorylation [60].The driving force for Ca2C entry is prin-
cipally determined by a mildly outwardly rectifying KC channel
(KSper) that, like CatSpers, is activated by intracellular alkaliniza-
tion [253]. Mouse KSper is encoded by mSlo3, a protein detected
only in testis [235, 253, 419]. In human sperm, such alkalinization
may result from the activation of Hv1, a proton channel [216].
Mutations in CatSpers are associated with syndromic and non-
syndromic male infertility [128]. In human ejaculated spermato-
zoa, progesterone (<50 nM) potentiates the CatSper current by
a non-genomic mechanism and acts synergistically with intracel-
lular alkalinisation [215, 343]. Sperm cells from infertile patients
with a deletion in CatSper2 gene lack ICatSper and the progesterone
response [331]. In addition, certain prostaglandins (e.g. PGF1α,
PGE1) also potentiate CatSper mediated currents [215, 343].
In human sperm, CatSper channels are also activated by various
small molecules including endocrine disrupting chemicals (EDC)
and proposed as a polymodal sensor [35, 35].
TPCs are the major NaC conductance in lysosomes; knocking out
TPC1 and TPC2 eliminates the NaC conductance and renders the
organelle’s membrane potential insensitive to changes in [NaC]
(31). The channels are regulated by luminal pH [41], PI(3,5)P2
[387], intracellular ATP and extracellular amino acids [42]. TPCs
are also involved in the NAADP-activated Ca2C release from lyso-
somal Ca2C stores [39, 243]. Mice lacking TPCs are viable but have
phenotypes including compromised lysosomal pH stability, re-
duced physical endurance [42], resistance to Ebola viral infection
[314] and fatty liver [110]. No major human disease-associated
TPC mutation has been reported.
Further Reading
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Cang C et al. (2014) The voltage-gated sodium channel TPC1 confers endolysosomal excitability.
Nat. Chem. Biol. 10: 463-9 [PMID:24776928]
Cang C et al. (2013) mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to
metabolic state. Cell 152: 778-90 [PMID:23394946]
Clapham DE et al. (2005) International Union of Pharmacology. L. Nomenclature and structure-
function relationships of CatSper and two-pore channels. Pharmacol. Rev. 57: 451-4
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Hildebrand MS et al. (2010) Genetic male infertility and mutation of CATSPER ion channels. Eur. J.
Hum. Genet. 18: 1178-84 [PMID:20648059]
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Lishko PV et al. (2010) The role of Hv1 and CatSper channels in sperm activation. J. Physiol. (Lond.)
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ology (Bethesda) 25: 165-75 [PMID:20551230]
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Cyclic nucleotide-regulated channels
Voltage-gated ion channels! Cyclic nucleotide-regulated channels
Overview: Cyclic nucleotide-gated (CNG) channels are respon-
sible for signalling in the primary sensory cells of the vertebrate
visual and olfactory systems. A standardised nomenclature
for CNG channels has been proposed by the NC-IUPHAR
subcommittee on voltage-gated ion channels [138].
CNG channels are voltage-independent cation channels formed as
tetramers. Each subunit has 6TM, with the pore-forming domain
between TM5 and TM6. CNG channels were first found in rod
photoreceptors [96, 166], where light signals through rhodopsin
and transducin to stimulate phosphodiesterase and reduce intra-
cellular cyclic GMP level. This results in a closure of CNG chan-
nels and a reduced ‘dark current’. Similar channels were found in
the cilia of olfactory neurons [252] and the pineal gland [86]. The
cyclic nucleotides bind to a domain in the C terminus of the sub-
unit protein: other channels directly binding cyclic nucleotides
include HCN, eag and certain plant potassium channels.
Nomenclature CNGA1 CNGA2 CNGA3 CNGB3
HGNC, UniProt CNGA1, P29973 CNGA2, Q16280 CNGA3, Q16281 CNGB3, Q9NQW8
Activators cyclic GMP (EC50 30 M) cyclic AMP cyclic GMP cyclic AMP (EC50 1 M) cyclic GMP (EC50 30 M) cyclic AMP –
Functional Characteristics γ = 25-30 pS PCa/PNa = 3.1 γ = 35 pS PCa/PNa = 6.8 γ = 40 pS PCa/PNa = 10.9 –
Inhibitors – – L-(cis)-diltiazem –
Channel blockers dequalinium (Antagonist) (pIC50 6.7)
[0mV] [312], L-(cis)-diltiazem (Antagonist)
(pKi 4) [-80mV – 80mV] [53]
dequalinium (Antagonist) (pIC50 5.6) [0mV]
[311]
– L-(cis)-diltiazem (Antagonist)
(pIC50 5.5) [0mV] [102] – Mouse
Comments: CNGA1, CNGA2 and CNGA3 express functional
channels as homomers. Three additional subunits CNGA4
(Q8IV77), CNGB1 (Q14028) and CNGB3 (Q9NQW8) do not, and
are referred to as auxiliary subunits. The subunit composi-
tion of the native channels is believed to be as follows. Rod:
CNGA13/CNGB1a; Cone: CNGA32/CNGB32; Olfactory neurons:
CNGA22/CNGA4/CNGB1b [287, 393, 420, 421, 423].
Hyperpolarisation-activated, cyclic nucleotide-gated (HCN)
The hyperpolarisation-activated, cyclic nucleotide-gated (HCN)
channels are cation channels that are activated by hyperpolar-
isation at voltages negative to -50 mV. The cyclic nucleotides
cyclic AMP and cyclic GMP directly activate the channels and
shift the activation curves of HCN channels to more positive volt-
ages, thereby enhancing channel activity. HCN channels underlie
pacemaker currents found in many excitable cells including car-
diac cells and neurons [82, 274]. In native cells, these currents
have a variety of names, such as Ih, Iq andIf. The four known HCN
channels have six transmembrane domains and form tetramers.
It is believed that the channels can form heteromers with each
other, as has been shown for HCN1 and HCN4 [7]. A standard-
ised nomenclature for HCN channels has been proposed
by the NC-IUPHAR subcommittee on voltage-gated ion
channels [138].
Searchable database: http://www.guidetopharmacology.org/index.jsp Cyclic nucleotide-regulated channels 5907
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Nomenclature HCN1 HCN2 HCN3 HCN4
HGNC, UniProt HCN1, O60741 HCN2, Q9UL51 HCN3, Q9P1Z3 HCN4, Q9Y3Q4
Activators cyclic AMP > cyclic GMP (both
weak)
cyclic AMP > cyclic GMP – cyclic AMP > cyclic GMP
Channel blockers ivabradine (Antagonist) (pIC50
5.7) [-40mV] [337], ZD7288
(Antagonist) (pIC50 4.7) [-40mV]
[336], CsC (Antagonist) (pIC50
3.7) [-40mV] [336]
ivabradine (Antagonist) (pIC50
5.6) [-40mV] [337] – Mouse,
ZD7288 (Antagonist) (pIC50 4.4)
[-40mV] [336], CsC (Antagonist)
(pIC50 3.7) [-40mV] [336]
ivabradine (Antagonist) (pIC50
5.7) [-40mV] [337], ZD7288
(Antagonist) (pIC50 4.5) [-40mV]
[336], CsC (Antagonist) (pIC50
3.8) [-40mV] [336]
ivabradine (Antagonist) (pIC50
5.7) [-40mV] [337], ZD7288
(Antagonist) (pIC50 4.7) [-40mV]
[336], CsC (Antagonist) (pIC50
3.8) [-40mV] [336]
Comments: HCN channels are permeable to both NaC and KC
ions, with a NaC/KC permeability ratio of about 0.2. Functionally,
they differ from each other in terms of time constant of activation
with HCN1 the fastest, HCN4 the slowest and HCN2 and HCN3
intermediate. The compounds ZD7288 [32] and ivabradine [38]
have proven useful in identifying and studying functional HCN
channels in native cells. Zatebradine and cilobradine are also use-
ful blocking agents.
Further Reading
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Potassium channels
Voltage-gated ion channels! Potassium channels
Overview: Potassium channels are fundamental regulators of ex-
citability. They control the frequency and the shape of action
potential waveform, the secretion of hormones and neurotrans-
mitters and cell membrane potential. Their activity may be reg-
ulated by voltage, calcium and neurotransmitters (and the sig-
nalling pathways they stimulate). They consist of a primary pore-
forming a subunit often associated with auxiliary regulatory sub-
units. Since there are over 70 different genes encoding K chan-
nels α subunits in the human genome, it is beyond the scope
of this guide to treat each subunit individually. Instead, chan-
nels have been grouped into families and subfamilies based on
their structural and functional properties. The three main families
are the 2TM (two transmembrane domain), 4TM and 6TM fami-
lies. A standardised nomenclature for potassium chan-
nels has been proposed by the NC-IUPHAR subcommit-
tees on potassium channels [106, 120, 191, 392].
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Calcium-activated potassium channels
Voltage-gated ion channels! Potassium channels! Calcium-activated potassium channels
Overview: The 6TM family of K channels comprises the voltage-gated KVsubfamilies, the KCNQ subfamily, the EAG subfamily (which includes herg channels), the Ca
2C-activated Slo subfamily (actually
with 6 or 7TM) and the Ca2C-activated SK subfamily. As for the 2TM family, the pore-forming a subunits form tetramers and heteromeric channels may be formed within subfamilies (e.g. KV1.1 with
KV1.2; KCNQ2 with KCNQ3).
Nomenclature KCa1.1 KCa2.1 KCa2.2 KCa2.3
HGNC, UniProt KCNMA1, Q12791 KCNN1, Q92952 KCNN2, Q9H2S1 KCNN3, Q9UGI6
Functional Characteristics Maxi KCa SKCa SKCa SKCa
Activators NS004, NS1619 EBIO (Agonist) Concentration range:
210 3M [-80mV] [284, 390], NS309
(Agonist) Concentration range:
310 8M-110 7M [-90mV] [341, 390]
NS309 (Agonist) (pEC50 6.2)
Concentration range: 310 8M-110 7M
[-90mV – -50mV] [283, 341, 390], EBIO
(Agonist) (pEC50 3.3) [-50mV] [283, 390],
EBIO (Agonist) (pEC50 3) Concentration
range: 210 3M [-100mV] [44, 284] – Rat
EBIO (Agonist) (pEC50
3.8) [-160mV – -120mV]
[390, 398], NS309
(Agonist) Concentration
range: 310 8M [-90mV]
[341, 390]
Inhibitors charybdotoxin, iberiotoxin,
tetraethylammonium
– – –
Channel blockers paxilline (Antagonist) (pKi 8.7) [0mV] [316]
– Mouse
UCL1684 (Antagonist) (pIC50 9.1) [-80mV]
[340, 390], apamin (Antagonist) (pIC50
7.9–8.5, median 8.1) [-80mV] [323, 338,
340], tetraethylammonium (Antagonist)
(pIC50 2.7) [390]
UCL1684 (Antagonist) (pIC50 9.6) [-40mV]
[94, 390], apamin (Antagonist) (pKd 9.4)
[-80mV] [161], tetraethylammonium
(Antagonist) (pIC50 2.7) [390]
apamin (Antagonist)
(pIC50 7.9–9.1) [-160mV
– -100mV] [358, 398],
UCL1684 (Antagonist)
(pIC50 8–9) [-80mV] [94,
390],
tetraethylammonium
(Antagonist) (pIC50 2.7)
[390]
Comments – The rat isoform does not form functional
channels when expressed alone in cell
lines. N- or C-terminal chimeric constructs
permit functional channels that are
insensitive to apamin [390]. Heteromeric
channels are formed between KCa2.1 and
2.2 subunits that show intermediate
sensitivity to apamin [63].
– –
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Nomenclature KCa3.1 KNa1.1 KNa1.2 KCa5.1
HGNC, UniProt KCNN4, O15554 KCNT1, Q5JUK3 KCNT2, Q6UVM3 KCNU1, A8MYU2
Functional Characteristics IKCa KNa KNa Sperm pH-regulated K
C
current, KSPER
Activators NS309 (Agonist) (pEC50 8) [-90mV] [341,
390], SKA-121 (Agonist) (pEC50 7) [67],
EBIO (Agonist) (pEC50 4.1–4.5) [-100mV –
-50mV] [284, 346, 390]
bithionol (Agonist) (pEC50 5–6) [414] –
Rat, niclosamide (Agonist) (pEC50 5.5)
[30], loxapine (Agonist) (pEC50 5.4) [30]
niflumic acid (Agonist) [71] –
Gating inhibitors – bepridil (Antagonist) (pIC50 5–6) [9, 27,
414] – Rat
– –
Channel blockers charybdotoxin (Inhibition) (pIC50 7.6–8.7)
[153, 157], TRAM-34 (Inhibition) (pKd
7.6–8) [193, 403]
quinidine (Antagonist) (pIC50 4) [414] –
Rat
Ba2C (Inhibition) (pIC50 3) [27], quinidine
(Inhibition) Concentration range:
110 3M [27] – Rat
tetraethylammonium
(pEC50 2.3) [319, 355] –
Mouse, quinidine [355] –
Mouse
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Inwardly rectifying potassium channels
Voltage-gated ion channels! Potassium channels! Inwardly rectifying potassium channels
Overview: The 2TM domain family of K channels are also known as the inward-rectifier K channel family. This family includes the strong inward-rectifier K channels (Kir2.x), the G-protein-activated
inward-rectifier K channels (Kir3.x) and the ATP-sensitive K channels (Kir6.x, which combine with sulphonylurea receptors (SUR)). The pore-forming a subunits form tetramers, and heteromeric channels
may be formed within subfamilies (e.g. Kir3.2 with Kir3.3).
Nomenclature Kir1.1 Kir2.1 Kir2.2
HGNC, UniProt KCNJ1, P48048 KCNJ2, P63252 KCNJ12, Q14500
Ion Selectivity and
Conductance
NH4
C [62pS] > KC [38. pS] > TlC [21pS] > RbC
[15pS] (Rat) [57, 134]
– –
Functional Characteristics Kir1.1 is weakly inwardly rectifying, as compared to
classical (strong) inward rectifiers.
IK1 in heart, ‘strong’ inward-rectifier current IK1in heart, ‘strong’ inward-rectifier current
Endogenous activators – PIP2 (Agonist) Concentration range:
110 5M-510 5M [-30mV] [142, 307, 334] –
Mouse
–
Endogenous inhibitors – – Intracellular Mg2C (pIC50 5) [40mV] [413]
Gating inhibitors – – Ba2C (Antagonist) Concentration range: 510 5M
[-150mV – -50mV] [349] – Mouse, CsC
(Antagonist) Concentration range:
510 6M-510 5M [-150mV – -50mV] [349] –
Mouse
Endogenous channel
blockers
– spermine (Antagonist) (pKd 9.1) [voltage dependent
40mV] [150, 415] – Mouse, spermidine
(Antagonist) (pKd 8.1) [voltage dependent 40mV]
[415] – Mouse, putrescine (Antagonist) (pKd 5.1)
[voltage dependent 40mV] [150, 415] – Mouse,
Intracellular Mg2C (Antagonist) (pKd 4.8) [voltage
dependent 40mV] [415] – Mouse
–
Channel blockers tertiapin-Q (Inhibition) (pIC50 8.9) [156], Ba
2C
(Antagonist) (pIC50 2.3–4.2) Concentration range:
110 4M [voltage dependent 0mV – -100mV] [134,
424] – Rat, CsC (Antagonist) (pIC50 2.9) [voltage
dependent -120mV] [424] – Rat
Ba2C (Antagonist) (pKd 3.9–5.6) Concentration
range: 110 6M-110 4M [voltage dependent 0mV
– -80mV] [6] – Mouse, CsC (Antagonist) (pKd
1.3–4) Concentration range: 310 5M-310 4M
[voltage dependent 0mV – -102mV] [3] – Mouse
–
Comments – Kir2.1 is also inhibited by intracellular polyamines Kir2.2 is also inhibited by intracellular polyamines
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Nomenclature Kir2.3 Kir2.4 Kir3.1 Kir3.2
HGNC, UniProt KCNJ4, P48050 KCNJ14, Q9UNX9 KCNJ3, P48549 KCNJ6, P48051
Functional Characteristics IK1 in heart, ‘strong’ inward-rectifier
current
IK1 in heart, ‘strong’ inward-rectifier
current
G-protein-activated inward-rectifier
current
G-protein-activated
inward-rectifier current
Endogenous activators – – PIP2 (Agonist) (pKd 6.3)
Concentration range: 510 5M
[physiological voltage] [142] –
Unknown
PIP2 (Agonist) (pKd 6.3)
Concentration range:
510 5M [physiological
voltage] [142] –
Unknown
Endogenous inhibitors – Intracellular Mg2C – –
Gating inhibitors – – – pimozide (Antagonist)
(pEC50 5.5) [-70mV]
[180] – Mouse
Endogenous channel blockers Intracellular Mg2C (Antagonist) (pKd
5) [voltage dependent 50mV] [222],
putrescine (Antagonist) Concentration
range: 510 5M-110 3M [-80mV –
80mV] [222], spermidine (Antagonist)
Concentration range:
2.510 5M-110 3M [-80mV –
80mV] [222], spermine (Antagonist)
Concentration range:
510 5M-110 3M [-80mV – 80mV]
[222]
– – –
Channel blockers Ba2C (Antagonist) (pIC50 5)
Concentration range:
310 6M-510 4M [-60mV] [233,
296, 356], CsC (Antagonist) (pKi
1.3–4.5) Concentration range:
310 6M-310 4M [0mV – -130mV]
[233]
CsC (Antagonist) (pKd 3–4.1) [voltage
dependent -60mV – -100mV] [143],
Ba2C (Antagonist) (pKd 3.3) [voltage
dependent 0mV] [143]
tertiapin-Q (Antagonist) (pIC50 7.9)
[156], Ba2C (Antagonist) (pIC50 4.7)
[73] – Rat
desipramine (Antagonist)
(pIC50 4.4) [-70mV]
[181] – Mouse
Comments Kir2.3 is also inhibited by intracellular
polyamines
Kir2.4 is also inhibited by intracellular
polyamines
Kir3.1 is also activated by Gβγ. Kir3.1
is not functional alone. The functional
expression of Kir3.1 in Xenopus oocytes
requires coassembly with the
endogenous Xenopus Kir3.5 subunit.
The major functional assembly in the
heart is the Kir3.1/3.4 heteromultimer,
while in the brain it is Kir3.1/3.2,
Kir3.1/3.3 and Kir3.2/3.3.
Kir3.2 is also activated by
Gβγ. Kir3.2 forms
functional heteromers
with Kir3.1/3.3.
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Nomenclature Kir3.3 Kir3.4 Kir4.1 Kir4.2
HGNC, UniProt KCNJ9, Q92806 KCNJ5, P48544 KCNJ10, P78508 KCNJ15, Q99712
Functional Characteristics G-protein-activated inward-rectifier
current
G-protein-activated inward-rectifier
current
Inward-rectifier current Inward-rectifier current
Endogenous activators PIP2 [129] PIP2 [20, 129] – –
Channel blockers – tertiapin-Q (Antagonist) (pIC50 7.9)
[156]
Ba2C (Antagonist) Concentration
range: 310 6M-110 3M [-160mV –
60mV] [185, 351, 354] – Rat, CsC
(Antagonist) Concentration range:
310 5M-310 4M [-160mV – 50mV]
[351] – Rat
Ba2C (Antagonist) Concentration
range: 110 5M-110 4M [-120mV –
100mV] [282] – Mouse, CsC
(Antagonist) Concentration range:
110 5M-110 4M [-120mV –
100mV] [282] – Mouse
Comments Kir3.3 is also activated by Gβγ Kir3.4 is also activated by Gβγ – –
Nomenclature Kir5.1 Kir6.1 Kir6.2 Kir7.1
HGNC, UniProt KCNJ16, Q9NPI9 KCNJ8, Q15842 KCNJ11, Q14654 KCNJ13, O60928
Associated subunits – SUR1, SUR2A, SUR2B SUR1, SUR2A, SUR2B –
Functional Characteristics Weakly inwardly rectifying ATP-sensitive, inward-rectifier current ATP-sensitive, inward-rectifier current Inward-rectifier current
Activators – cromakalim, diazoxide (Agonist)
Concentration range: 210 4M [-60mV]
[411] – Mouse, minoxidil, nicorandil
(Agonist) Concentration range: 310 4M
[-60mV – 60mV] [411] – Mouse
diazoxide (Agonist) (pEC50 4.2)
[physiological voltage] [146] – Mouse,
cromakalim (Agonist) Concentration
range: 310 5M [-60mV] [147] – Mouse,
minoxidil, nicorandil
–
Inhibitors – glibenclamide, tolbutamide glibenclamide, tolbutamide –
Channel blockers Ba2C (Antagonist) Concentration range:
310 3M [-120mV – 20mV] [353] – Rat
– – Ba2C (Antagonist) (pKi 3.2)
[voltage dependent -100mV] [90,
190, 192, 277], CsC (Antagonist)
(pKi 1.6) [voltage dependent
-100mV] [90, 190, 277]
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Two-P potassium channels
Voltage-gated ion channels! Potassium channels! Two-P potassium channels
Overview: The 4TM family of K channels are thought to underlie
many background K currents in native cells. They are open at all
voltages and regulated by a wide array of neurotransmitters and
biochemical mediators. The primary pore-forming α-subunit con-
tains two pore domains (indeed, they are often referred to as two-
pore domain K channels or K2P) and so it is envisaged that they
form functional dimers rather than the usual K channel tetramers.
There is some evidence that they can form heterodimers within
subfamilies (e.g. K2P3.1 with K2P9.1). There is no current, clear,
consensus on nomenclature of 4TM K channels, nor on the divi-
sion into subfamilies [106]. The suggested division into subfam-
ilies, below, is based on similarities in both structural and func-
tional properties within subfamilies.
Nomenclature K2P1.1 K2P2.1 K2P3.1 K2P4.1 K2P5.1
HGNC, UniProt KCNK1, O00180 KCNK2, O95069 KCNK3, O14649 KCNK4, Q9NYG8 KCNK5, O95279
Functional Characteristics Background current Background current Background current.
Knock-out of the kcnk3 gene
leads to a prolonged QT
interval in mice [77].
Background current Background current
Endogenous activators – arachidonic acid (pEC50 5) – arachidonic acid (Positive)
Concentration range:
510 6M-510 5M [168] –
Rat
–
Activators – halothane, riluzole halothane (Positive) (pEC50 3)
Concentration range:
110 3M [389] – Rat
riluzole (Positive)
Concentration range:
310 6M-110 4M [88]
–
Channel blockers – – anandamide (Inhibition)
(pIC50 5.6) [230]
– –
Comments K2P1.1 is inhibited by acid
pHo
K2P2.1 is also activated by
stretch, heat and acid pHi
K2P3.1 is also activated by
alkaline pHo and inhibited by
acid pHo
K2P4.1 is also activated by
heat, acid pHi, and
membrane stretch
K2P5.1 is activated by alkaline
pHo
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Nomenclature K2P6.1 K2P7.1 K2P9.1 K2P10.1 K2P12.1
HGNC, UniProt KCNK6, Q9Y257 KCNK7, Q9Y2U2 KCNK9, Q9NPC2 KCNK10, P57789 KCNK12, Q9HB15
Functional Characteristics Unknown Unknown Background current Background current Unknown
Endogenous activators – – – arachidonic acid [203] –
Activators – – halothane halothane, riluzole –
Inhibitors – – anandamide, ruthenium red – halothane
Comments – – K2P9.1 is also inhibited by acid pHo K2P10.1 is also activated by heat,
acid pHi, and membrane stretch
–
Nomenclature K2P13.1 K2P15.1 K2P16.1 K2P17.1 K2P18.1
HGNC, UniProt KCNK13, Q9HB14 KCNK15, Q9H427 KCNK16, Q96T55 KCNK17, Q96T54 KCNK18, Q7Z418
Functional Characteristics Background current Unknown Background current Background current Background current
Endogenous inhibitors – – – – arachidonic acid
Inhibitors halothane – – – –
Comments – – K2P16.1 is activated by alkaline pHo K2P17.1 is activated by alkaline pHo –
Comments: The K2P7.1, K2P15.1 and K2P12.1 subtypes, when expressed in isolation, are nonfunctional. All 4TM channels are insensitive to the classical potassium channel blockers tetraethylammonium
and fampridine, but are blocked to varying degrees by Ba2C ions.
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Voltage-gated potassium channels
Voltage-gated ion channels! Potassium channels! Voltage-gated potassium channels
Overview: The 6TM family of K channels comprises the voltage-gated KVsubfamilies, the KCNQ subfamily, the EAG subfamily (which includes herg channels), the Ca
2C-activated Slo subfamily (actually
with 6 or 7TM) and the Ca2C-activated SK subfamily. As for the 2TM family, the pore-forming a subunits form tetramers and heteromeric channels may be formed within subfamilies (e.g. KV1.1 with
KV1.2; KCNQ2 with KCNQ3).
Nomenclature Kv1.1 Kv1.2 Kv1.3 Kv1.4 Kv1.5
HGNC, UniProt KCNA1, Q09470 KCNA2, P16389 KCNA3, P22001 KCNA4, P22459 KCNA5, P22460
Associated subunits Kv1.2, Kv1.4, Kvβ1 and Kvβ2
[68]
Kv1.1, Kv1.4, Kv β1 and Kv β2
[68]
Kv1.1, Kv1.2, Kv1.4, Kv1.6 ,
Kv β1 and Kv β2 [68]
Kv1.1, Kv1.2, Kvβ1 and Kvβ2
[68]
Kv β1 and Kv β2
Functional Characteristics KV KV KV KA KV
Channel blockers α-dendrotoxin (pEC50 7.7–9)
[113, 144] – Rat, margatoxin
(Inhibition) (pIC50 8.4) [19],
tetraethylammonium
(Inhibition) (pKd 3.5) [113] –
Mouse
margatoxin (Inhibition) (pIC50
11.2) [19], α-dendrotoxin
(pIC50 7.8–9.4) [113, 144] –
Rat, noxiustoxin (pKd 8.7)
[113] – Rat
margatoxin (pIC50 10–10.3)
[100, 103], noxiustoxin (pKd
9) [113] – Mouse,
tetraethylammonium
(moderate) (pKd 2) [113] –
Mouse
fampridine (pIC50 1.9) [344] –
Rat
–
Selective channel blockers – – correolide (pIC50 7.1) [95] – –
Nomenclature Kv1.6 Kv1.7 Kv1.8 Kv2.1 Kv2.2
HGNC, UniProt KCNA6, P17658 KCNA7, Q96RP8 KCNA10, Q16322 KCNB1, Q14721 KCNB2, Q92953
Associated subunits Kv β1 and Kv β2 Kv β1 and Kv β2 Kv β1 and Kv β2 Kv5.1, Kv6.1-6.4, Kv8.1-8.2
and Kv9.1-9.3
Kv5.1, Kv6.1-6.4,
Kv8.1-8.2 and
Kv9.1-9.3
Functional Characteristics KV KV KV KV –
Channel blockers α-dendrotoxin (pIC50 7.7)
[114], tetraethylammonium
(pIC50 2.2) [114]
fampridine (pIC50 3.6) [162]
– Mouse
fampridine (pIC50 2.8) [195] tetraethylammonium (Pore
blocker) (pIC50 2) [127] –
Rat
fampridine (pIC50
2.8) [318],
tetraethylammonium
(pIC50 2.6) [318]
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Nomenclature Kv3.1 Kv3.2 Kv3.3 Kv3.4 Kv4.1
HGNC, UniProt KCNC1, P48547 KCNC2, Q96PR1 KCNC3, Q14003 KCNC4, Q03721 KCND1, Q9NSA2
Associated subunits – – – MiRP2 is an associated subunit
for Kv3.4
KChIP and KChAP
Functional Characteristics KV KV KA KA KA
Channel blockers fampridine (pIC50 4.5) [113] –
Mouse, tetraethylammonium
(pIC50 3.7) [113] – Mouse
fampridine (pIC50 4.6) [210] –
Rat, tetraethylammonium (pIC50
4.2) [210] – Rat
tetraethylammonium (pIC50 3.9)
[367] – Rat
tetraethylammonium (pIC50 3.5)
[309, 321] – Rat
fampridine (pIC50 2)
[149]
Selective channel blockers – – – sea anemone toxin BDS-I (pIC50
7.3) [84] – Rat
–
Nomenclature Kv4.2 Kv4.3 Kv5.1 Kv6.1 Kv6.2 Kv6.3 Kv6.4
HGNC, UniProt KCND2, Q9NZV8 KCND3, Q9UK17 KCNF1, Q9H3M0 KCNG1, Q9UIX4 KCNG2, Q9UJ96 KCNG3, Q8TAE7 KCNG4, Q8TDN1
Associated subunits KChIP and KChAP KChIP and KChAP – – – – –
Functional Characteristics KA KA – – – – –
Nomenclature Kv7.1 Kv7.2 Kv7.3 Kv7.4 Kv7.5
HGNC, UniProt KCNQ1, P51787 KCNQ2, O43526 KCNQ3, O43525 KCNQ4, P56696 KCNQ5, Q9NR82
Functional Characteristics cardiac IK5 M current M current – –
Activators – retigabine (pEC50 5.6) [357] retigabine (pEC50 6.2) [357] retigabine (pEC50 5.2) [357] retigabine (pEC50 5)
[89]
Inhibitors linopirdine (pIC50 4.4) [271] –
Mouse
– linopirdine (pIC50 5.4) [385] –
Rat
– –
Channel blockers XE991 (Antagonist) (pKd 6.1)
[384]
XE991 (pIC50 6.2) [385],
linopirdine (pIC50 5.3) [385],
tetraethylammonium (pIC50
3.5–3.9) [121, 394]
– XE991 (pIC50 5.3) [348],
linopirdine (pIC50 4.9) [348],
tetraethylammonium (pIC50
1.3) [14]
linopirdine (pKd 4.8)
[202]
(Sub)family-selective channel
blockers
– – – – XE991 (pIC50 4.2)
[320]
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Nomenclature Kv8.1 Kv8.2 Kv9.1 Kv9.2 Kv9.3 Kv10.1 Kv10.2
HGNC, UniProt KCNV1, Q6PIU1 KCNV2, Q8TDN2 KCNS1, Q96KK3 KCNS2, Q9ULS6 KCNS3, Q9BQ31 KCNH1, O95259 KCNH5, Q8NCM2
Nomenclature Kv11.1 Kv11.2 Kv11.3 Kv12.1 Kv12.2 Kv12.3
HGNC, UniProt KCNH2, Q12809 KCNH6, Q9H252 KCNH7, Q9NS40 KCNH8, Q96L42 KCNH3, Q9ULD8 KCNH4, Q9UQ05
Associated subunits minK (KCNE1) and MiRP1 (KCNE2) minK (KCNE1) minK (KCNE1) minK (KCNE1) minK (KCNE1)
and MiRP2
(KCNE3)
–
Functional Characteristics cardiac IKR – – – – –
Channel blockers astemizole (pIC50 9) [426], terfenadine (pIC50 7.3)
[303], disopyramide (Inhibition) (pIC50 4) [167]
– – – – –
(Sub)family-selective channel
blockers
E4031 (pIC50 8.1) [425] – – – – –
Selective channel blockers dofetilide (Inhibition) (pKi 8.2) [328], ibutilide
(pIC50 7.6–8) [167, 290]
– – – – –
Comments RPR260243 is an activator of Kv11.1 [163]. – – – – –
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Transient Receptor Potential channels
Voltage-gated ion channels! Transient Receptor Potential channels
Overview:
The TRP superfamily of channels (nomenclature as agreed by
NC-IUPHAR [65, 402]), whose foundermember is theDrosophila
Trp channel, exists in mammals as six families; TRPC, TRPM,
TRPV, TRPA, TRPP and TRPML based on amino acid homologies.
TRP subunits contain six putative transmembrane domains and
assemble as homo- or hetero-tetramers to form cation selective
channels with diverse modes of activation and varied permeation
properties (reviewed by [273]). Established, or potential, physio-
logical functions of the individual members of the TRP families are
discussed in detail in the recommended reviews and a compilation
edited by Islam [151]. The established, or potential, involvement
of TRP channels in disease is reviewed in [174, 258] and [260], to-
gether with a special edition of Biochemica et Biophysica Acta on the
subject [258]. The pharmacology of most TRP channels is poorly
developed [402]. Broad spectrum agents are listed in the tables
along with more selective, or recently recognised, ligands that are
flagged by the inclusion of a primary reference. Most TRP chan-
nels are regulated by phosphoinostides such as PtIns(4,5)P2and
IP3 although the effects reported are often complex, occasion-
ally contradictory, and likely to be dependent upon experimen-
tal conditions, such as intracellular ATP levels (reviewed by [261,
310, 372]). Such regulation is generally not included in the ta-
bles. When thermosensitivity is mentioned, it refers specifically
to a high Q10 of gating, often in the range of 10-30, but does
not necessarily imply that the channel’s function is to act as a
’hot’ or ’cold’ sensor. In general, the search for TRP activators has
led to many claims for temperature sensing, mechanosensation,
and lipid sensing. All proteins are of course sensitive to energies
of binding, mechanical force, and temperature, but the issue is
whether the proposed input is within a physiologically relevant
range resulting in a response.
TRPA (ankyrin) family
TRPA1 is the sole mammalian member of this group (reviewed by
[101]). TRPA1 activation of sensory neurons contribute to no-
ciception [158, 238, 339]. Pungent chemicals such as mustard
oil (AITC), allicin, and cinnamaldehyde activate TRPA1 by mod-
ification of free thiol groups of cysteine side chains, especially
those located in its amino terminus [21, 133, 226, 228]. Alkenals
with α, β-unsaturated bonds, such as propenal (acrolein), bute-
nal (crotylaldehyde), and 2-pentenal can react with free thiols via
Michael addition and can activate TRPA1. However, potency ap-
pears to weaken as carbon chain length increases [12, 21]. Cova-
lent modification leads to sustained activation of TRPA1. Chemi-
cals including carvacrol, menthol, and local anesthetics reversibly
activate TRPA1 by non-covalent binding [164, 201, 407, 408].
TRPA1 is not mechanosensitive under physiological conditions,
but can be activated by cold temperatures [165, 429]. The electron
cryo-EM structure of TRPA1 [279] indicates that it is a 6-TM ho-
motetramer. Each subunit of the channel contains two short ‘pore
helices’ pointing into the ion selectivity filter, which is big enough
to allow permeation of partially hydrated Ca2C ions. A coiled-
coil domain in the carboxy-terminal region forms the cytoplas-
mic stalk of the channel, and is surrounded by 16 ankyrin repeat
domains, which are speculated to interdigitate with an overlying
helix-turn-helix and putative β-sheet domain containing cysteine
residues targeted by electrophilic TRPA1 agonists. The TRP do-
main, a helix at the base of S6, runs perpendicular to the pore
helices suspended above the ankyrin repeats below, where it may
contribute to regulation of the lower pore. The coiled-coil stalk
mediates bundling of the four subunits through interactions be-
tween predicted α-helices at the base of the channel.
TRPC (canonical) family
Members of the TRPC subfamily (reviewed by [2, 8, 25, 29, 99,
172, 278, 298]) fall into the subgroups outlined below. TRPC2 (not
tabulated) is a pseudogene in man. It is generally accepted that all
TRPC channels are activated downstream of Gq=11-coupled recep-
tors, or receptor tyrosine kinases (reviewed by [294, 364, 402]).
A comprehensive listing of G-protein coupled receptors that acti-
vate TRPC channels is given in [2]. Hetero-oligomeric complexes
of TRPC channels and their association with proteins to form sig-
nalling complexes are detailed in [8] and [173]. TRPC channels
have frequently been proposed to act as store-operated channels
(SOCs) (or compenents of mulimeric complexes that form SOCs),
activated by depletion of intracellular calcium stores (reviewed by
[8, 56, 285, 295, 315, 416]), However, the weight of the evidence
is that they are not directly gated by conventional store-operated
mechanisms, as established for Stim-gated Orai channels. TRPC
channels are not mechanically gated in physiologically relevant
ranges of force. All members of the TRPC family are blocked by
2-APB and SKF96365 [124, 125]. Activation of TRPC channels by
lipids is discussed by [25].
TRPC1/C4/C5 subgroup
TRPC4/C5 may be distinguished from other TRP channels by their
potentiation by micromolar concentrations of La3C.
TRPC3/C6/C7 subgroup
All members are activated by diacylglycerol independent of pro-
tein kinase C stimulation [125].
TRPM (melastatin) family
Members of the TRPM subfamily (reviewed by [97, 124, 285, 422])
fall into the five subgroups outlined below.
TRPM1/M3 subgroup
TRPM1 exists as five splice variants and is involved in normal
melanocyte pigmentation [268] and is also a visual transduction
channel in retinal ON bipolar cells [183]. TRPM3 (reviewed by
[270]) exists as multiple splice variants four of which (mTRPM3α1,
mTRPM3α2, hTRPM3a and hTRPM31325) have been characterised
and found to differ significantly in their biophysical properties.
TRPM3 may contribute to the detection of noxious heat [376].
TRPM2
TRPM2 is activated under conditions of oxidative stress (reviewed
by [412]). Numerous splice variants of TRPM2 exist which differ
in their activation mechanisms [87]. The C-terminal domain con-
tains a TRP motif, a coiled-coil region, and an enzymatic NUDT9
homologous domain. TRPM2 appears not to be activated by NAD,
NAAD, or NAADP, but is directly activated by ADPRP (adenosine-
5’-O-disphosphoribose phosphate) [365].
TRPM4/5 subgroup
TRPM4 and TRPM5 have the distinction within all TRP channels
of being impermeable to Ca2C [402]. A splice variant of TRPM4
(i.e.TRPM4b) and TRPM5 are molecular candidates for endoge-
nous calcium-activated cation (CAN) channels [115]. TRPM4 has
been shown to be an important regulator of Ca2C entry in to mast
cells [368] and dendritic cell migration [18]. TRPM5 in taste re-
ceptor cells of the tongue appears essential for the transduction of
sweet, amino acid and bitter stimuli [212].
TRPM6/7 subgroup
TRPM6 and 7 combine channel and enzymatic activities
(‘chanzymes’). These channels have the unusual property of per-
meation by divalent (Ca2C, Mg2C, Zn2C) andmonovalent cations,
high single channel conductances, but overall extremely small
inward conductance when expressed to the plasma membrane.
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They are inhibited by internal Mg2C at 0.6 mM, around the free
level of Mg2C in cells. Whether they contribute to Mg2C home-
ostasis is a contentious issue. When either gene is deleted in mice,
the result is embryonic lethality. The C-terminal kinase region is
cleaved under unknown stimuli, and the kinase phosphorylates
nuclear histones.
TRPM8
Is a channel activated by cooling and pharmacological agents
evoking a ‘cool’ sensation and participates in the thermosensa-
tion of cold temperatures [23, 66, 81] reviewed by [179, 220, 248,
373].
TRPML (mucolipin) family
The TRPML family [297, 300, 417] consists of three mammalian
members (TRPML1-3). TRPML channels are probably restricted to
intracellular vesicles and mutations in the gene (MCOLN1) encod-
ing TRPML1 (mucolipin-1) are one cause of the neurodegenerative
disordermucolipidosis type IV (MLIV) in man. TRPML1 is a cation
selective ion channel that is important for sorting/transport of en-
dosomes in the late endocytotic pathway and specifically fusion
between late endosome-lysosome hybrid vesicles. TRPML3 is im-
portant for hair cell maturation, stereocilia maturation and intra-
cellular vesicle transport. A naturally occurring gain of function
mutation in TRPML3 (i.e. A419P) results in the varitint waddler
(Va) mouse phenotype (reviewed by [262, 300]).
TRPP (polycystin) family
The TRPP family (reviewed by [78, 80, 104, 137, 399]) or PKD2
family is comprised of PKD2, PKD2L1 and PKD2L2, which have
been renamed TRPP1, TRPP2 and TRPP3, respectively [402]. They
are clearly distinct from the PKD1 family, whose function is un-
known. Although still being sorted out, TRPP family members
appear to be 6TM spanning nonselective cation channels.
TRPV (vanilloid) family
Members of the TRPV family (reviewed by [369]) can broadly be
divided into the non-selective cation channels, TRPV1-4 and the
more calcium selective channels TRPV5 and TRPV6.
TRPV1-V4 subfamily
TRPV1 is involved in the development of thermal hyperalgesia
following inflammation and may contribute to the detection of
noxius heat (reviewed by [293, 335, 347]). Numerous splice vari-
ants of TRPV1 have been described, some of which modulate the
activity of TRPV1, or act in a dominant negative manner when co-
expressed with TRPV1 [322]. The pharmacology of TRPV1 chan-
nels is discussed in detail in [117] and [375]. TRPV2 is probably not
a thermosensor in man [275], but has recently been implicated in
innate immunity [214]. TRPV3 and TRPV4 are both thermosen-
sitive. There are claims that TRPV4 is also mechanosensitive, but
this has not been established to be within a physiological range in
a native environment [43, 209].
TRPV5/V6 subfamily
Under physiological conditions, TRPV5 and TRPV6 are calcium
selective channels involved in the absorption and reabsorption of
calcium across intestinal and kidney tubule epithelia (reviewed by
[397, 428]).
Nomenclature TRPA1
HGNC, UniProt TRPA1, O75762
Chemical activators –
Other chemical activators Isothiocyanates (covalent) and 1,4-dihydropyridines (non-covalent)
Physical activators Cooling (<17ÆC) (disputed)
Functional Characteristics γ = 87-100 pS; conducts mono- and di-valent cations non-selectively (PCa/PNa = 0.84); outward rectification; activated by elevated intracellular Ca
2C
Activators acrolein (Agonist) (pEC50 5.3) [physiological voltage] [21], allicin (Agonist) (pEC50 5.1) [physiological voltage] [22], 1
9-tetrahydrocannabinol (Agonist) (pEC50 4.9) [-60mV]
[158], nicotine (non-covalent) (pEC50 4.8) [-75mV] [352], thymol (non-covalent) (pEC50 4.7) Concentration range: 6.210
 6M-2.510 5M [199], URB597 (Agonist) (pEC50
4.6) [257], (-)-menthol (Partial agonist) (pEC50 4–4.5) [164, 405], cinnamaldehyde (Agonist) (pEC50 4.2) [physiological voltage] [15] – Mouse, icilin (Agonist) Concentration
range: 110 4M [physiological voltage] [339] – Mouse
Selective activators chlorobenzylidene malononitrile (covalent) (pEC50 6.7) [37], formalin (covalent. This level of activity is also observed for rat TRPA1) (pEC50 3.4) [228, 238] – Mouse
Channel blockers AP18 (Inhibition) (pIC50 5.5) [292], ruthenium red (Inhibition) (pIC50 5.5) [-80mV] [250] – Mouse, HC030031 (Inhibition) (pIC50 5.2) [238]
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Nomenclature TRPC1 TRPC2 TRPC3
HGNC, UniProt TRPC1, P48995 TRPC2, – TRPC3, Q13507
Chemical activators NO-mediated cysteine S-nitrosation – diacylglycerols
Physical activators membrane stretch (likely direct) –
Functional Characteristics It is not yet clear that TRPC1 forms a homomer. It
does form heteromers with TRPC4 and TRPC5
– γ = 66 pS; conducts mono and di-valent cations
non-selectively (PCa/PNa = 1.6); monovalent cation
current suppressed by extracellular Ca2C; dual (inward
and outward) rectification
Activators – DOG (Agonist) Concentration range: 110 4M
[-80mV] [223] – Mouse, SAG (Agonist)
Concentration range: 110 4M [-80mV] [223] –
Mouse
–
Channel blockers 2-APB (Antagonist) [-70mV] [342], Gd3C
(Antagonist) Concentration range: 210 5M [-70mV]
[427], GsMTx-4, La3C (Antagonist) Concentration
range: 110 4M [-70mV] [342], SKF96365
2-APB (Antagonist) Concentration range: 510 5M
[-70mV – 80mV] [223] – Mouse
Gd3C (Antagonist) (pEC50 7) [-60mV] [122], BTP2
(Antagonist) (pIC50 6.5) [-80mV] [126], La
3C
(Antagonist) (pIC50 5.4) [-60mV] [122], 2-APB
(Antagonist) (pIC50 5) [physiological voltage] [211],
ACAA, KB-R7943, Ni2C, Pyr3 [175], SKF96365
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Nomenclature TRPC4 TRPC5 TRPC6 TRPC7
HGNC, UniProt TRPC4, Q9UBN4 TRPC5, Q9UL62 TRPC6, Q9Y210 TRPC7, Q9HCX4
Chemical activators – – – diacylglycerols
Other chemical activators NO-mediated cysteine S-nitrosation,
potentiation by extracellular protons
NO-mediated cysteine S-nitrosation
(disputed), potentiation by extracellular
protons
Diacylglycerols –
Physical activators – Membrane stretch (likely indirect) Membrane stretch (likely indirect) –
Functional Characteristics γ = 30 -41 pS, conducts mono and
di-valent cations non-selectively (PCa/PNa =
1.1 - 7.7); dual (inward and outward)
rectification
γ = 41-63 pS; conducts mono-and di-valent
cations non-selectively (PCa/PNa = 1.8 -
9.5); dual rectification (inward and
outward) as a homomer, outwardly
rectifying when expressed with TRPC1 or
TRPC4
γ = 28-37 pS; conducts mono and divalent
cations with a preference for divalents
(PCa/PNa = 4.5-5.0); monovalent cation
current suppressed by extracellular Ca2C
and Mg2C, dual rectification (inward and
outward), or inward rectification
γ = 25-75 pS; conducts mono
and divalent cations with a
preference for divalents (PCa/
PCs = 5.9); modest outward
rectification (monovalent
cation current recorded in the
absence of extracellular
divalents); monovalent cation
current suppressed by
extracellular Ca2C and Mg2C
Endogenous activators – intracellular Ca2C (at negative potentials)
(pEC50 6.2), lysophosphatidylcholine
20-HETE, arachidonic acid,
lysophosphatidylcholine
–
Activators La3C (M range) Gd3C Concentration range: 110 4M,
La3C (M range), Pb2C Concentration
range: 510 6M, daidzein, genistein
(independent of tyrosine kinase inhibition)
[400]
flufenamate, hyp 9 [204], hyperforin [205] –
Endogenous channel
blockers
– – – –
Channel blockers ML204 (pIC50 5.5) [240], 2-APB, La
3C
(mM range), SKF96365, niflumic acid
(Antagonist) Concentration range:
310 5M [-60mV] [380] – Mouse
KB-R7943 (Inhibition) (pIC50 5.9) [187],
ML204 (pIC50 5) [240], 2-APB
(Antagonist) (pIC50 4.7) [-80mV] [410],
BTP2, GsMTx-4, La3C (Antagonist)
Concentration range: 510 3M [-60mV]
[159] – Mouse, SKF96365,
chlorpromazine, flufenamic acid
Gd3C (Antagonist) (pIC50 5.7) [-60mV]
[148] – Mouse, SKF96365 (Antagonist)
(pIC50 5.4) [-60mV] [148] – Mouse, La
3C
(pIC50 5.2), amiloride (Antagonist)
(pIC50 3.9) [-60mV] [148] – Mouse, Cd
2C
(Antagonist) (pIC50 3.6) [-60mV] [148] –
Mouse, 2-APB, ACAA, GsMTx-4,
Extracellular HC, KB-R7943, ML9
2-APB, La3C (Antagonist)
Concentration range:
110 4M [-60mV] [272] –
Mouse, SKF96365
(Antagonist) Concentration
range: 2.510 5M [-60mV]
[272] – Mouse, amiloride
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Nomenclature TRPM1 TRPM2 TRPM3 TRPM4
HGNC, UniProt TRPM1, Q7Z4N2 TRPM2, O94759 TRPM3, Q9HCF6 TRPM4, Q8TD43
Other channel blockers – – – Intracellular nucleotides
including ATP,
adenosine diphosphate,
adenosine 5’-monophosphate
and AMP-PNP with an IC50
range of 1.3-1.9 M
Other chemical
activators
– Agents producing reactive oxygen
(e.g. H2O2) and nitrogen (e.g. GEA
3162) species
– –
Physical activators – Heat 35ÆC heat (Q10 = 7.2 between 15 - 25
ÆC;
Vriens et al., 2011), hypotonic cell
swelling [376]
Membrane depolarization
(V1=2 = -20 mV to + 60 mV
dependent upon conditions)
in the presence of elevated
[Ca2C]i, heat (Q10 = 8.5 @
+25 mV between 15 and
25ÆC)
Functional
Characteristics
Conducts mono- and di-valent cations
non-selectively, dual rectification
(inward and outward)
γ = 52-60 pS at negative potentials, 76
pS at positive potentials; conducts
mono- and di-valent cations
non-selectively (PCa/PNa = 0.6-0.7);
non-rectifying; inactivation at
negative potentials; activated by
oxidative stress probably via PARP-1,
PARP inhibitors reduce activation by
oxidative stress, activation inhibited
by suppression of APDR formation by
glycohydrolase inhibitors
TRPM31235: γ = 83 pS (Na
C current),
65 pS (Ca2C current); conducts mono
and di-valent cations non-selectively
(PCa/PNa = 1.6) TRPM3α1: selective
for monovalent cations (PCa/PCs 0.1);
TRPM3α2: conducts mono- and
di-valent cations non-selectively
(PCa/PCs = 1-10); Outwardly rectifying
(magnitude varies between spice
variants)
γ = 23 pS (within the range 60
to +60 mV); permeable to
monovalent cations;
impermeable to Ca2C; strong
outward rectification; slow
activation at positive
potentials, rapid deactivation
at negative potentials,
deactivation blocked by
decavanadate
Endogenous activators pregnenolone sulphate [194] intracellular cADPR (Agonist) (pEC50
5) [-80mV – -60mV] [24, 184, 360],
intracellular ADP ribose (Agonist)
(pEC50 3.9–4.4) [-80mV] [289],
intracellular Ca2C (via calmodulin),
H2O2 (Agonist) Concentration range:
510 7M-510 5M [physiological
voltage] [98, 123, 189, 332, 391],
arachidonic acid (Potentiation)
Concentration range:
110 5M-310 5M [physiological
voltage] [123]
sphingosine (Agonist) (pEC50 4.9)
[physiological voltage] [112],
epipregnanolone sulphate [231],
pregnenolone sulphate [377],
sphinganine (Agonist) Concentration
range: 210 5M [physiological
voltage] [112]
intracellular Ca2C (Agonist)
(pEC50 3.9–6.3) [-100mV –
100mV] [259, 263, 264, 350]
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Activators – GEA 3162 nifedipine BTP2 (Agonist) (pEC50 8.1) [-80mV] [350],
decavanadate (Agonist) (pEC50 5.7)
[-100mV] [263]
Gating inhibitors – – 2-APB (Antagonist) Concentration range:
110 4M [physiological voltage] [410]
flufenamic acid (Antagonist) (pIC50 5.6)
[100mV] [366] – Mouse, clotrimazole
(Antagonist) Concentration range:
110 6M-110 5M [100mV] [267]
Endogenous channel blockers Zn2C (pIC50 6) Zn
2C (pIC50 6), extracellular H
C Mg2C (Antagonist) Concentration range:
910 3M [-80mV – 80mV] [269] – Mouse,
extracellular NaC (TRPM3α2 only)
–
Channel blockers 2-APB (Antagonist) (pIC50 6.1) [-60mV]
[361], ACAA (Antagonist) (pIC50 5.8)
[physiological voltage] [188], clotrimazole
(Antagonist) Concentration range:
310 6M-310 5M [-60mV – -15mV]
[131], econazole (Antagonist)
Concentration range: 310 6M-310 5M
[-60mV – -15mV] [131], flufenamic acid
(Antagonist) Concentration range:
510 5M-110 3M [-60mV – -50mV]
[130, 361], miconazole (Antagonist)
Concentration range: 110 5M [-60mV]
[361]
Gd3C (Antagonist) Concentration range:
110 4M [-80mV – 80mV] [111, 198],
La3C (Antagonist) Concentration range:
110 4M [physiological voltage] [111,
198], mefenamic acid [177], pioglitazone
(independent of PPAR-γ) [232],
rosiglitazone [232], troglitazone
9-phenanthrol (pIC50 4.6–4.8) [108],
spermine (Antagonist) (pIC50 4.2)
[100mV] [265], adenosine (pIC50 3.2)
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Nomenclature TRPM5 TRPM6 TRPM7 TRPM8
HGNC, UniProt TRPM5, Q9NZQ8 TRPM6, Q9BX84 TRPM7, Q96QT4 TRPM8, Q7Z2W7
EC number – 2.7.11.1 2.7.11.1 –
Other chemical activators – constitutively active, activated by
reduction of intracellular Mg2C
activation of PKA agonist activities are temperature
dependent and potentiated by cooling
Physical activators membrane depolarization (V1=2 = 0 to +
120 mV dependent upon conditions),
heat (Q10 = 10.3 @ -75 mV between 15
and 25ÆC)
– – depolarization (V1=2 +50 mV at 15
ÆC),
cooling (< 22-26ÆC)
Functional Characteristics γ = 15-25 pS; conducts monovalent
cations selectively (PCa/PNa = 0.05);
strong outward rectification; slow
activation at positive potentials, rapid
inactivation at negative potentials;
activated and subsequently desensitized
by [Ca2C]I
γ= 40-87 pS; permeable to mono- and
di-valent cations with a preference for
divalents (Mg2C > Ca2C; PCa/PNa =
6.9), conductance sequence Zn2C >
Ba2C > Mg2C= Ca2C = Mn2C > Sr2C >
Cd2C> Ni2C; strong outward
rectification abolished by removal of
extracellular divalents, inhibited by
intracellular Mg2C (IC50 = 0.5 mM) and
ATP
γ = 40-105 pS at negative and positive
potentials respectively; conducts
mono-and di-valent cations with a
preference for monovalents (PCa/PNa =
0.34); conductance sequence Ni2C >
Zn2C > Ba2C = Mg2C > Ca2C = Mn2C
> Sr2C > Cd2C; outward rectification,
decreased by removal of extracellular
divalent cations; inhibited by
intracellular Mg2C, Ba2C, Sr2C, Zn2C,
Mn2C and Mg.ATP (disputed); activated
by and intracellular alkalinization;
sensitive to osmotic gradients
γ = 40-83 pS at positive potentials;
conducts mono- and di-valent cations
non-selectively (PCa/PNa = 1.0-3.3);
pronounced outward rectification;
demonstrates densensitization to
chemical agonists and adaptation to a
cold stimulus in the presence of Ca2C;
modulated by lysophospholipids and
PUFAs
Endogenous activators intracellular Ca2C (Agonist) (pEC50
4.5–6.2) [-80mV – 80mV] [139, 217,
366] – Mouse
extracellular HC (Potentiation),
intracellular Mg2C
intracellular ATP (Potentiation),
Extracellular HC (Potentiation),
cyclic AMP (elevated cAMP levels)
–
Activators – 2-APB (Agonist) (pEC50 3.4–3.7)
[-120mV – 100mV] [207]
2-APB Concentration range: >110 3M
[249] – Mouse
icilin (Agonist) (pEC50 6.7–6.9)
[physiological voltage] [10, 26] –
Mouse, (-)-menthol (inhibited by
intracellular Ca2C) (pEC50 4.6) [-120mV
– 160mV] [371]
Selective activators – – – WS-12 (Full agonist) (pEC50 4.9)
[physiological voltage] [224, 325] – Rat
Searchable database: http://www.guidetopharmacology.org/index.jsp Transient Receptor Potential channels 5926
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13349/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. British Journal of Pharmacology (2015) 172, 5904–5941
(continued)
Endogenous channel
blockers
– Mg2C (inward current mediated by
monovalent cations is blocked) (pIC50
5.5–6), Ca2C (inward current mediated
by monovalent cations is blocked)
(pIC50 5.3–5.3)
– –
Channel blockers flufenamic acid (pIC50 4.6), intracellular
spermine (pIC50 4.4), Extracellular H
C
(pIC50 3.2)
ruthenium red (pIC50 7) [voltage
dependent -120mV]
spermine (Inhibition) (pKi 5.6) [-110mV
– 80mV] [186] – Rat, 2-APB (Inhibition)
(pIC50 3.8) [-100mV – 100mV] [207] –
Mouse, carvacrol (Inhibition) (pIC50
3.5) [-100mV – 100mV] [276] – Mouse,
Mg2C (Antagonist) (pIC50 2.5) [80mV]
[249] – Mouse, La3C (Antagonist)
Concentration range: 210 3M
[-100mV – 100mV] [313] – Mouse
BCTC (Antagonist) (pIC50 6.1)
[physiological voltage] [26] – Mouse,
2-APB (Antagonist) (pIC50 4.9–5.1)
[100mV – -100mV] [141, 254] – Mouse,
capsazepine (Antagonist) (pIC50 4.7)
[physiological voltage] [26] – Mouse,
1
9-tetrahydrocannabinol,
5-benzyloxytryptamine, ACAA, AMTB
[196], La3C, NADA, anandamide,
cannabidiol, clotrimazole, linoleic acid
Comments TRPM5 is not blocked by ATP – 2-APB acts as a channel blocker in the
M range.
cannabidiol and
1
9-tetrahydrocannabinol are examples
of cannabinoids. TRPM8 is insensitive to
ruthenium red. icilin requires
intracellular Ca2C for full agonist activity.
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Nomenclature TRPML1 TRPML2 TRPML3
HGNC, UniProt MCOLN1, Q9GZU1 MCOLN2, Q8IZK6 MCOLN3, Q8TDD5
Activators TRPML1Va: Constitutively active, current
potentiated by extracellular acidification
(equivalent to intralysosomal acidification)
TRPML2Va: Constitutively active, current
potentiated by extracellular acidification
(equivalent to intralysosomal acidification)
TRPML3Va: Constitutively active, current inhibited
by extracellular acidification (equivalent to
intralysosomal acidicification) Wild type TRPML3:
Activated by NaC-free extracellular (extracytosolic)
solution and membrane depolarization, current
inhibited by extracellular acidification (equivalent
to intralysosomal acidicification)
Functional Characteristics TRPML1Va: γ = 40 pS and 76-86 pS at very
negative holding potentials with Fe2C and
monovalent cations as charge carriers, respectively;
conducts NaC KC>CsC and divalent cations
(Ba2C>Mn2C>Fe2C>Ca2C> Mg2C>
Ni2C>Co2C> Cd2C>Zn2CCu2C) protons;
monovalent cation flux suppressed by divalent
cations (e.g. Ca2C, Fe2C); inwardly rectifying
TRPML1Va: Conducts NaC; monovalent cation flux
suppressed by divalent cations; inwardly rectifying
TRPML3Va: γ = 49 pS at very negative holding
potentials with monovalent cations as charge
carrier; conducts NaC > KC > CsC with maintained
current in the presence of NaC, conducts Ca2C and
Mg2C, but not Fe2C, impermeable to protons;
inwardly rectifying Wild type TRPML3: γ = 59 pS at
negative holding potentials with monovalent
cations as charge carrier; conducts NaC > KC >
CsC and Ca2C (PCa/PK 350), slowly inactivates in
the continued presence of NaC within the
extracellular (extracytosolic) solution; outwardly
rectifying
Channel blockers – – Gd3C (Antagonist) (pIC50 4.7) [-80mV] [251] –
Mouse
Nomenclature TRPP1 TRPP2 TRPP3
HGNC, UniProt PKD2, Q13563 PKD2L1, Q9P0L9 PKD2L2, Q9NZM6
Activators – Calmidazolium (in primary cilia): 10 M –
Functional Characteristics The channel properties of TRPP1 (PKD2)
have not been determined with certainty
Currents have been measured directly from primary cilia and also when expressed on
plasma membranes. Primary cilia appear to contain heteromeric TRPP2 + PKD1-L1,
underlying a gently outwardly rectifying nonselective conductance (PCa/PNa 6:
PKD1-L1 is a 12 TM protein of unknown topology). Primary cilia heteromeric channels
have an inward single channel conductance of 80 pS and an outward single channel
conductance of 95 pS. Presumed homomeric TRPP2 channels are gently outwardly
rectifying. Single channel conductance is 120 pS inward, 200 pS outward [74].
–
Channel blockers – phenamil (pIC50 6.9), benzamil (pIC50 6), ethylisopropylamiloride (pIC50 5),
amiloride (pIC50 3.8), Gd
3C Concentration range: 110 4M [-50mV] [54], La3C
Concentration range: 110 4M [-50mV] [54], flufenamate
–
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Nomenclature TRPV1 TRPV2 TRPV3
HGNC, UniProt TRPV1, Q8NER1 TRPV2, Q9Y5S1 TRPV3, Q8NET8
Other chemical activators NO-mediated cysteine S-nitrosation – NO-mediated cysteine S-nitrosytion
Physical activators depolarization (V1=2 0 mV at 35
ÆC), noxious heat (>
43ÆC at pH 7.4)
noxious heat (> 35ÆC; rodent, not human) [255] depolarization (V1=2 +80 mV, reduced to more
negative values following heat stimuli), heat (23ÆC -
39ÆC, temperature threshold reduces with repeated
heat challenge)
Functional Characteristics γ = 35 pS at - 60 mV; 77 pS at + 60 mV, conducts mono
and divalent cations with a selectivity for divalents
(PCa/PNa = 9.6); voltage- and time- dependent outward
rectification; potentiated by ethanol;
activated/potentiated/upregulated by PKC stimulation;
extracellular acidification facilitates activation by PKC;
desensitisation inhibited by PKA; inhibited by Ca2C/
calmodulin; cooling reduces vanilloid-evoked currents;
may be tonically active at body temperature
Conducts mono- and divalent cations (PCa/PNa =
0.9-2.9); dual (inward and outward) rectification;
current increases upon repetitive activation by heat;
translocates to cell surface in response to IGF-1 to
induce a constitutively active conductance, translocates
to the cell surface in response to membrane stretch
γ = 197 pS at = +40 to +80 mV, 48 pS at negative
potentials; conducts mono- and divalent cations;
outward rectification; potentiated by arachidonic acid
Endogenous activators extracellular HC (at 37ÆC) (pEC50 5.4), 12S-HPETE
(Agonist) (pEC50 5.1) [-60mV] [145] – Rat, 15S-HPETE
(Agonist) (pEC50 5.1) [-60mV] [145] – Rat, LTB4
(Agonist) (pEC50 4.9) [-60mV] [145] – Rat, 5S-HETE
– –
Activators resiniferatoxin (Agonist) (pEC50 8.4) [physiological
voltage] [330], capsaicin (Agonist) (pEC50 7.5)
[-100mV – 160mV] [371], camphor,
diphenylboronic anhydride, phenylacetylrinvanil [13]
2-APB (pEC50 5) [255, 301] – Rat,
1
9-tetrahydrocannabinol (pEC50 4.8) [301] – Rat,
cannabidiol (pEC50 4.5) [301], probenecid (pEC50 4.5)
[16] – Rat, 2-APB (Agonist) (pEC50 3.8–3.9)
[physiological voltage] [141, 160] – Mouse,
diphenylboronic anhydride (Agonist) Concentration
range: 110 4M [-80mV] [61, 160] – Mouse
incensole acetate (pEC50 4.8) [244] – Mouse, 2-APB
(Full agonist) (pEC50 4.6) [-80mV – 80mV] [62] –
Mouse, diphenylboronic anhydride (Full agonist)
(pEC50 4.1–4.2) [voltage dependent -80mV – 80mV]
[61] – Mouse, (-)-menthol (pEC50 1.7) [-80mV – 80mV]
[227] – Mouse, camphor (Full agonist) Concentration
range: 110 3M-210 3M [-60mV] [242] – Mouse,
carvacrol (Full agonist) Concentration range: 510 4M
[-80mV – 80mV] [408] – Mouse, eugenol (Full agonist)
Concentration range: 310 3M [-80mV – 80mV] [408]
– Mouse, thymol (Full agonist) Concentration range:
510 4M [-80mV – 80mV] [408] – Mouse
Selective activators olvanil (Agonist) (pEC50 7.7) [physiological voltage]
[330], DkTx (pEC50 6.6) [physiological voltage] [33] –
Rat
– 6-tert-butyl-m-cresol (pEC50 3.4) [374] – Mouse
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(continued)
Channel blockers 5’-iodoresiniferatoxin (pIC50 8.4),
6-iodo-nordihydrocapsaicin (pIC50 8), BCTC
(Antagonist) (pIC50 7.5) [52], capsazepine (Antagonist)
(pIC50 7.4) [-60mV] [237], ruthenium red (pIC50
6.7–7), 2-APB, NADA, allicin, anandamide
ruthenium red (pIC50 6.2), La
3C, SKF96365, TRIM
(Inhibition) Concentration range: 510 4M [160] –
Mouse, amiloride
diphenyltetrahydrofuran (Antagonist) (pIC50 5–5.2)
[-80mV – 80mV] [61] – Mouse, ruthenium red
(Inhibition) Concentration range: 110 6M [-60mV]
[286] – Mouse
Selective channel blockers AMG517 (pIC50 9) [31], AMG628 (pIC50 8.4) [383] –
Rat, A425619 (pIC50 8.3) [91], A778317 (pIC50 8.3)
[28], SB366791 (pIC50 8.2) [119], JYL1421
(Antagonist) (pIC50 8) [388] – Rat, JNJ17203212
(Antagonist) (pIC50 7.8) [physiological voltage] [345],
SB705498 (Antagonist) (pIC50 7.1) [118], SB452533
– –
Labelled ligands [3H]A778317 (Channel blocker) (pKd 8.5) [28],
[125I]resiniferatoxin (Channel blocker, Antagonist)
(pIC50 8.4) [-50mV] [378] – Rat, [
3H]resiniferatoxin
(Activator)
– –
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Nomenclature TRPV4 TRPV5 TRPV6
HGNC, UniProt TRPV4, Q9HBA0 TRPV5, Q9NQA5 TRPV6, Q9H1D0
Activators – constitutively active (with strong buffering of
intracellular Ca2C)
constitutively active (with strong buffering of
intracellular Ca2C)
Other channel blockers – Pb2C = Cu2C = Gd3C > Cd2C > Zn2C > La3C > Co2C
> Fe2
–
Other chemical activators Epoxyeicosatrieonic acids and NO-mediated cysteine
S-nitrosylation
– –
Physical activators Constitutively active, heat (> 24ÆC - 32ÆC), mechanical
stimuli
– –
Functional Characteristics γ = 60 pS at -60 mV, 90-100 pS at +60 mV; conducts
mono- and di-valent cations with a preference for
divalents (PCa/PNa =6-10); dual (inward and outward)
rectification; potentiated by intracellular Ca2C via
Ca2C/ calmodulin; inhibited by elevated intracellular
Ca2Cvia an unknown mechanism (IC50 = 0.4 M)
γ = 59-78 pS for monovalent ions at negative
potentials, conducts mono- and di-valents with high
selectivity for divalents (PCa/PNa > 107); voltage- and
time- dependent inward rectification; inhibited by
intracellular Ca2C promoting fast inactivation and slow
downregulation; feedback inhibition by Ca2C reduced
by calcium binding protein 80-K-H; inhibited by
extracellular and intracellular acidosis; upregulated by
1,25-dihydrovitamin D3
γ = 58-79 pS for monovalent ions at negative
potentials, conducts mono- and di-valents with high
selectivity for divalents (PCa/PNa > 130); voltage- and
time-dependent inward rectification; inhibited by
intracellular Ca2C promoting fast and slow inactivation;
gated by voltage-dependent channel blockade by
intracellular Mg2C; slow inactivation due to
Ca2C-dependent calmodulin binding; phosphorylation
by PKC inhibits Ca2C-calmodulin binding and slow
inactivation; upregulated by 1,25-dihydroxyvitamin D3
Activators phorbol 12-myristate 13-acetate (Agonist) (pEC50 7.9)
[physiological voltage] [406]
– 2-APB (Potentiation)
Selective activators GSK1016790A (pEC50 8.7) [physiological voltage]
[359], 4α-PDH (pEC50 7.1) [physiological voltage]
[176] – Mouse, RN1747 (pEC50 6.1) [physiological
voltage] [370], bisandrographolide (Agonist) (pEC50 6)
[-60mV] [333] – Mouse, 4α-PDD (Agonist)
Concentration range: 310 7M [physiological voltage]
[406]
– –
Channel blockers Gd3C, La3C, ruthenium red (Inhibition) Concentration
range: 110 6M [physiological voltage] [154],
ruthenium red (Inhibition) Concentration range:
210 7M [physiological voltage] [116] – Rat
ruthenium red (pIC50 6.9), Mg
2C, econazole,
miconazole
ruthenium red (Antagonist) (pIC50 5) [-80mV] [136] –
Mouse, Cd2C, La3C, Mg2C
Selective channel blockers HC067047 (Inhibition) (pIC50 7.3) [-40mV] [93],
RN1734 (Inhibition) (pIC50 5.6) [physiological voltage]
[370]
– –
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Comments:
TRPA (ankyrin) family
Agents activating TRPA1 in a covalent manner are thiol reactive
electrophiles that bind to cysteine and lysine residues within the
cytoplasmic domain of the channel [133, 225]. TRPA1 is activated
by a wide range of endogenous and exogenous compounds and
only a few representative examples are mentioned in the table:
an exhaustive listing can be found in [17]. In addition, TRPA1 is
potently activated by intracellular zinc (EC50 = 8 nM) [11, 140].
TRPM (melastatin) family
Ca2C activates all splice variants of TRPM2, but other activa-
tors listed are effective only at the full length isoform [87].
Inhibition of TRPM2 by clotrimazole, miconazole, econazole,
flufenamic acid is largely irreversible. TRPM4 exists as multi-
ple spice variants: data listed are for TRPM4b. The sensitivity
of TRPM4b and TRPM5 to activation by [Ca2C]i demonstrates a
pronounced and time-dependent reduction following excision of
inside-out membrane patches [366]. The V1=2 for activation of
TRPM4 and TRPM5 demonstrates a pronounced negative shift
with increasing temperature. Activation of TRPM8 by depolariza-
tion is strongly temperature-dependent via a channel-closing rate
that decreases with decreasing temperature. The V1=2 is shifted
in the hyperpolarizing direction both by decreasing temperature
and by exogenous agonists, such as (-)-menthol [371] whereas an-
tagonists produce depolarizing shifts in V1=2 [247]. The V1=2 for
the native channel is far more positive than that of heterologously
expressed TRPM8 [247]. It should be noted that (-)-menthol and
structurally related compounds can elicit release of Ca2C from the
endoplasmic reticulum independent of activation of TRPM8 [229].
Intracellular pHmodulates activation of TRPM8 by cold and icilin,
but not (-)-menthol [10].
TRPML (mucolipin) family
Data in the table are for TRPML proteins mutated (i.e TRPML1Va ,
TRPML2Va and TRPML3Va) at loci equivalent to TRPML3 A419P to
allow plasma membrane expression when expressed in HEK-293
cells and subsequent characterisation by patch-clamp recording
[85, 109, 169, 251, 409]. Data for wild type TRPML3 are also tab-
ulated [169, 170, 251, 409]. It should be noted that alternative
methodologies, particularly in the case of TRPML1, have resulted
in channels with differing biophysical characteristics (reviewed by
[297]).
TRPP (polycystin) family
Data in the table are extracted from [72, 80] and [326]. Broadly
similar single channel conductance, mono- and di-valent cation
selectivity and sensitivity to blockers are observed for TRPP2 co-
expressed with TRPP1 [79]. Ca2C, Ba2C and Sr2C permeate TRPP3,
but reduce inward currents carried by NaC. Mg2C is largely imper-
meant and exerts a voltage dependent inhibition that increases
with hyperpolarization.
TRPV (vanilloid) family
Activation of TRPV1 by depolarisation is strongly temperature-
dependent via a channel opening rate that increases with in-
creasing temperature. The V1=2 is shifted in the hyperpolar-
izing direction both by increasing temperature and by exoge-
nous agonists [371]. The sensitivity of TRPV4 to heat, but not
4α-PDD is lost upon patch excision. TRPV4 is activated by
anandamide and arachidonic acid following P450 epoxygenase-
dependent metabolism to 5,6-epoxyeicosatrienoic acid (reviewed
by [266]). Activation of TRPV4 by cell swelling, but not heat,
or phorbol esters, is mediated via the formation of epoxye-
icosatrieonic acids. Phorbol esters bind directly to TRPV4.
TRPV5 preferentially conducts Ca2C under physiological condi-
tions, but in the absence of extracellular Ca2C, conducts mono-
valent cations. Single channel conductances listed for TRPV5 and
TRPV6 were determined in divalent cation-free extracellular solu-
tion. Ca2C-induced inactivation occurs at hyperpolarized poten-
tials when Ca2C is present extracellularly. Single channel events
cannot be resolved (probably due to greatly reduced conductance)
in the presence of extracellular divalent cations. Measurements
of PCa/PNa for TRPV5 and TRPV6 are dependent upon ionic con-
ditions due to anomalous mole fraction behaviour. Blockade of
TRPV5 and TRPV6 by extracellular Mg2C is voltage-dependent.
Intracellular Mg2C also exerts a voltage dependent block that
is alleviated by hyperpolarization and contributes to the time-
dependent activation and deactivation of TRPV6 mediated mono-
valent cation currents. TRPV5 and TRPV6 differ in their kinetics
of Ca2C-dependent inactivation and recovery from inactivation.
TRPV5 and TRPV6 function as homo- and hetero-tetramers.
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Voltage-gated calcium channels
Voltage-gated ion channels! Voltage-gated calcium channels
Overview: Calcium (Ca2C) channels are voltage-gated ion chan-
nels present in the membrane of most excitable cells. The nomen-
clature for Ca2Cchannels was proposed by [92] and approved
by the NC-IUPHAR Subcommittee on Ca2C channels [50].
Ca2C channels form hetero-oligomeric complexes. The α1 sub-
unit is pore-forming and provides the binding site(s) for prac-
tically all agonists and antagonists. The 10 cloned α1-subunits
can be grouped into three families: (1) the high-voltage activated
dihydropyridine-sensitive (L-type, CaV1.x) channels; (2) the high-
voltage activated dihydropyridine-insensitive (CaV2.x) channels
and (3) the low-voltage-activated (T-type, CaV3.x) channels. Each
α1 subunit has four homologous repeats (I-IV), each repeat having
six transmembrane domains and a pore-forming region between
transmembrane domains S5 and S6. Gating is thought to be asso-
ciated with the membrane-spanning S4 segment, which contains
highly conserved positive charges. Many of the α1-subunit genes
give rise to alternatively spliced products. At least for high-voltage
activated channels, it is likely that native channels comprise co-
assemblies of α1, β and α2-Æ subunits. The γ subunits have not
been proven to associate with channels other than the α1s skele-
tal muscle Cav1.1 channel. The α2-Æ1 and α2-Æ2 subunits bind
gabapentin and pregabalin.
Nomenclature Cav1.1 Cav1.2 Cav1.3 Cav1.4 Cav2.1
HGNC, UniProt CACNA1S, Q13698 CACNA1C, Q13936 CACNA1D, Q01668 CACNA1F, O60840 CACNA1A, O00555
Functional Characteristics L-type calcium current: High
voltage-activated, slow
voltage dependent
inactivation
L-type calcium current: High
voltage-activated, slow
voltage-dependent
inactivation, rapid
calcium-dependent
inactivation
L-type calcium current:
Voltage-activated, slow
voltage-dependent
inactivation, more rapid
calcium-dependent
inactivation
L-type calcium current:
Moderate voltage-activated,
slow voltage-dependent
inactivation
P/Q-type calcium current:
Moderate voltage-activated,
moderate voltage-dependent
inactivation
Activators (-)-(S)-BayK8644, FPL64176,
SZ(+)-(S)-202-791
(-)-(S)-BayK8644, FPL64176
Concentration range:
110 6M-510 6M [219] –
Rat, SZ(+)-(S)-202-791
(-)-(S)-BayK8644 (-)-(S)-BayK8644 –
Gating inhibitors nifedipine (Antagonist) nifedipine (Antagonist) nitrendipine (Inhibition)
(pIC50 8.4) [329]
– –
Selective gating inhibitors – – – – !-agatoxin IVA (P current
component: Kd = 2nM, Q
component Kd= >100nM)
(pIC50 7–8.7) [-100mV –
-90mV] [34, 241] – Rat,
!-agatoxin IVB (pKd 8.5)
[-80mV] [4] – Rat
Channel blockers diltiazem (Antagonist),
verapamil (Antagonist)
diltiazem (Antagonist),
verapamil (Antagonist)
verapamil (Antagonist) – –
(Sub)family-selective
channel blockers
calciseptine (Antagonist) calciseptine (Antagonist) – – !-conotoxin MVIIC (pIC50
8.2–9.2) Concentration range:
210 6M-510 6M
[physiological voltage] [206] –
Rat
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(continued)
Comments – – Cav1.3 activates more
negative potentials than
Cav1.2 and is incompletely
inhibited by dihydropyridine
antagonists.
Cav1.4 is less sensitive to
dihydropyridine antagonists
than other Cav1 channels
–
Nomenclature Cav2.2 Cav2.3 Cav3.1 Cav3.2 Cav3.3
HGNC, UniProt CACNA1B, Q00975 CACNA1E, Q15878 CACNA1G, O43497 CACNA1H, O95180 CACNA1I, Q9P0X4
Functional Characteristics N-type calcium current: High
voltage-activated, moderate
voltage-dependent
inactivation
R-type calcium current:
Moderate voltage-activated,
fast voltage-dependent
inactivation
T-type calcium current: Low
voltage-activated, fast
voltage-dependent
inactivation
T-type calcium current: Low
voltage-activated, fast
voltage-dependent
inactivation
T-type calcium current: Low
voltage-activated, moderate
voltage-dependent
inactivation
Gating inhibitors – – kurtoxin (Antagonist) (pIC50
7.3–7.8) [-90mV] [58, 327] –
Rat
kurtoxin (Antagonist) (pIC50
7.3–7.6) [-90mV] [58, 327] –
Rat
–
Selective gating inhibitors – SNX482 (Antagonist) (pIC50
7.5–8) [physiological voltage]
[256]
– – –
Channel blockers – Ni2C (Antagonist) (pIC50 4.6)
[-90mV] [396]
mibefradil (Antagonist) (pIC50
6–6.6) [-110mV – -100mV]
[234], Ni2C (Antagonist)
(pIC50 3.6–3.8) [voltage
dependent -90mV] [197] – Rat
mibefradil (Antagonist) (pIC50
5.9–7.2, median 6.8) [-110mV
– -80mV] [234], Ni2C
(Antagonist) (pIC50 4.9–5.2)
[voltage dependent -90mV]
[197]
mibefradil (Antagonist) (pIC50
5.8) [-110mV] [234], Ni2C
(Antagonist) (pIC50 3.7–4.1)
[voltage dependent -90mV]
[197] – Rat
(Sub)family-selective channel
blockers
!-conotoxin GVIA
(Antagonist) (pIC50 10.4)
[-80mV] [206] – Rat,
!-conotoxin MVIIC
(Antagonist) (pIC50 6.1–8.5,
median 8.2) [-80mV] [132,
206, 236] – Rat
– – – –
Comments: In many cell types, P and Q current components cannot be adequately separated and many researchers in the field have adopted the terminology ‘P/Q-type’ current when referring to either
component. Both of these physiologically defined current types are conducted by alternative forms of Cav2.1. Ziconotide (a synthetic peptide equivalent to !-conotoxin MVIIA) has been approved for
the treatment of chronic pain [395].
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Voltage-gated proton channel
Voltage-gated ion channels! Voltage-gated proton channel
Overview: The voltage-gated proton channel (provisionally de-
noted Hv1) is a putative 4TM proton-selective channel gated by
membrane depolarization and which is sensitive to the transmem-
brane pH gradient [45, 75, 76, 305, 317]. The structure of Hv1 is
homologous to the voltage sensing domain (VSD) of the superfam-
ily of voltage-gated ion channels (i.e. segments S1 to S4) and con-
tains no discernable pore region [305, 317]. Proton flux through
Hv1 is instead most likely mediated by a water wire completed in a
crevice of the protein when the voltage-sensing S4 helix moves in
response to a change in transmembrane potential [304, 401]. Hv1
expresses largely as a dimer mediated by intracellular C-terminal
coiled-coil interactions [208] but individual promoters nonethe-
less support gated HC flux via separate conduction pathways [182,
200, 291, 362]. Within dimeric structures, the two protomers do
not function independently, but display co-operative interactions
during gating resulting in increased voltage sensitivity, but slower
activation, of the dimeric,versusmonomeric, complexes [107, 363]
.
Nomenclature Hv1
HGNC, UniProt HVCN1, Q96D96
Functional Characteristics Activated by membrane depolarization mediating macroscopic currents with time-, voltage- and pH-dependence; outwardly
rectifying; voltage dependent kinetics with relatively slow current activation sensitive to extracellular pH and temperature,
relatively fast deactivation; voltage threshold for current activation determined by pH gradient (1pH = pHo -pHi) across the
membrane
Channel blockers Zn2C (pIC50 5.7–6.3), Cd
2C (pIC50 5)
Comments: The voltage threshold (Vthr) for activation of Hv1
is not fixed but is set by the pH gradient across the membrane
such that Vthr is positive to the Nernst potential for H
C, which en-
sures that only outwardly directed flux of HC occurs under phys-
iological conditions [45, 75, 76]. Phosphorylation of Hv1 within
the N-terminal domain by PKC enhances the gating of the chan-
nel [245]. Tabulated IC50 values for Zn
2+ and Cd2C are for het-
erologously expressed human and mouse Hv1 [305, 317]. Zn
2C
is not a conventional pore blocker, but is coordinated by two,
or more, external protonation sites involving histamine residues
[305]. Zn2C binding may occur at the dimer interface between
pairs of histamine residues from both monomers where it may
interfere with channel opening [246]. Mouse knockout stud-
ies demonstrate that Hv1 participates in charge compensation
in granulocytes during the respiratory burst of NADPH oxidase-
dependent reactive oxygen species production that assists in the
clearance of bacterial pathogens [306]. Additional physiological
functions of Hv1 are reviewed by [45].
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Voltage-gated sodium channels
Voltage-gated ion channels! Voltage-gated sodium channels
Overview: Sodium channels are voltage-gated sodium-selective
ion channels present in the membrane of most excitable cells.
Sodium channels comprise of one pore-forming α subunit, which
may be associated with either one or two β subunits [152]. α-
Subunits consist of four homologous domains (I-IV), each contain-
ing six transmembrane segments (S1-S6) and a pore-forming loop.
The positively charged fourth transmembrane segment (S4) acts
as a voltage sensor and is involved in channel gating. The crystal
structure of the bacterial NavAb channel has revealed a number
of novel structural features compared to earlier potassium chan-
nel structures including a short selectivity filter with ion selectiv-
ity determined by interactions with glutamate side chains [280].
Interestingly, the pore region is penetrated by fatty acyl chains
that extend into the central cavity which may allow the entry of
small, hydrophobic pore-blocking drugs [280]. Auxiliary β1, β2,
β3 and β4 subunits consist of a large extracellular N-terminal do-
main, a single transmembrane segment and a shorter cytoplasmic
domain.
The nomenclature for sodium channels was proposed
by Goldin et al., (2000) [105] and approved by the
NC-IUPHAR Subcommittee on sodium channels (Catter-
all et al., 2005, [48]).
Nomenclature Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5
HGNC, UniProt SCN1A, P35498 SCN2A, Q99250 SCN3A, Q9NY46 SCN4A, P35499 SCN5A, Q14524
Functional Characteristics Activation V0.5 = -20 mV. Fast
inactivation ( = 0.7 ms for
peak sodium current).
Activation V0.5 = -24 mV. Fast
inactivation ( = 0.8 ms for
peak sodium current).
Activation V0.5 = -24 mV. Fast
inactivation (0.8 ms)
Activation V0.5 = -30 mV. Fast
inactivation (0.6 ms)
Activation V0.5 = -26 mV. Fast
inactivation ( = 1 ms for peak
sodium current).
(Sub)family-selective activators batrachotoxin, veratridine batrachotoxin (Agonist) (pKd
9.1) [physiological voltage]
[213] – Rat, veratridine (Partial
agonist) (pKd 5.2)
[physiological voltage] [49] –
Rat
batrachotoxin, veratridine batrachotoxin (Full agonist)
Concentration range:
510 6M [-100mV] [386] –
Rat, veratridine (Partial
agonist) Concentration range:
210 4M [-100mV] [386] –
Rat
batrachotoxin (Full agonist)
(pKd 7.6) [physiological
voltage] [324] – Rat,
veratridine (Partial agonist)
(pEC50 6.3) [-30mV] [381] –
Rat
(Sub)family-selective channel
blockers
saxitoxin (Pore blocker),
tetrodotoxin (Pore blocker)
Concentration range:
110 8M
saxitoxin (Pore blocker) (pIC50
8.8) [-120mV] [36] – Rat,
tetrodotoxin (Pore blocker)
(pIC50 8) [-120mV] [36] – Rat,
lacosamide (Antagonist)
(pIC50 4.5) [-80mV] [1] – Rat
tetrodotoxin (Pore blocker)
(pIC50 8.4) [55], saxitoxin
(Pore blocker)
saxitoxin (Pore blocker) (pIC50
8.4) [-100mV] [288] – Rat,
tetrodotoxin (Pore blocker)
(pIC50 7.6) [-120mV] [51],
-conotoxin GIIIA (Pore
blocker) (pIC50 5.9) [-100mV]
[51]
tetrodotoxin (Pore blocker)
(pKd 5.8) [-80mV] [69, 418] –
Rat
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Nomenclature Nav1.6 Nav1.7 Nav1.8 Nav1.9
HGNC, UniProt SCN8A, Q9UQD0 SCN9A, Q15858 SCN10A, Q9Y5Y9 SCN11A, Q9UI33
Functional Characteristics Activation V0.5 = -29 mV. Fast
inactivation (1 ms)
Activation V0.5 = -27 mV. Fast
inactivation (0.5 ms)
Activation V0.5 = -16 mV.
Inactivation (6 ms)
Activation V0.5 = -32 mV. Slow
inactivation (16 ms)
(Sub)family-selective activators batrachotoxin, veratridine batrachotoxin, veratridine – –
(Sub)family-selective channel
blockers
tetrodotoxin (Pore blocker) (pIC50
9) [-130mV] [83] – Rat, saxitoxin
(Pore blocker)
tetrodotoxin (Pore blocker) (pIC50
7.6) [-100mV] [178], saxitoxin
(Pore blocker) (pIC50 6.2) [379]
tetrodotoxin (Pore blocker) (pIC50
4.2) [-60mV] [5] – Rat
tetrodotoxin (Pore blocker) (pIC50
4.4) [-120mV] [70] – Rat
Selective channel blockers – – PF-01247324 (Pore blocker)
(pIC50 6.7) [voltage dependent]
[281]
–
Comments: Sodium channels are also blocked by local anaes-
thetic agents, antiarrythmic drugs and antiepileptic drugs. In gen-
eral, these drugs are not highly selective among channel subtypes.
There are two clear functional fingerprints for distinguishing dif-
ferent subtypes. These are sensitivity to tetrodotoxin (NaV1.5,
NaV1.8 and NaV1.9 are much less sensitive to block) and rate of
fast inactivation (NaV1.8 and particularly NaV1.9 inactivate more
slowly). All sodium channels also have a slow inactivation process
that is engaged during long depolarizations (>100 msec) or repet-
itive trains of stimuli. All sodium channel subtypes are blocked by
intracellular QX-314.
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